[Articles] Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
December 10, 2018
- The Lancet 392, 10162 (2018)
Author: Christopher C Parker, Nicholas D James, Christopher D Brawley, Noel W Clarke, Alex P Hoyle, Adnan Ali, Alastair W S Ritchie, Gerhardt Attard, Simon Chowdhury, William Cross, David P Dearnaley, Silke Gillessen, Clare Gilson, Robert J Jones, Ruth E Langley, Zafar I Malik, Malcolm D Mason, David Matheson, Robin Millman, J Martin Russell, George N Thalmann, Claire L Amos, Roberto Alonzi, Amit Bahl, Alison Birtle, Omar Din, Hassan Douis, Chinnamani Eswar, Joanna Gale, Melissa R Gannon, Sai Jonnada, Sara Khaksar, Jason F Lester, Joe M O'Sullivan, Omi A Parikh, Ian D Pedley, Delia M Pudney, Denise J Sheehan, Narayanan Nair Srihari, Anna T H Tran, Mahesh K B Parmar, Matthew R Sydes, Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators
Radiotherapy to the prostate did not improve overall survival for unselected patients with newly diagnosed metastatic prostate cancer.